Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer
Copyright © 2024 Elsevier Ltd. All rights reserved..
BACKGROUND: The immuno-modulatory effects of ionizing radiation are well-known and preclinical studies suggest a synergistic effect of combining radiotherapy (RT) and IO. However, data regarding the clinical activity and safety of this approach are limited.
METHODS: We present the cases of two patients with SCCHN primary progressing to PDL1-based IO within a clinical trial (NCT03383094), that received subsequent but not concurrent palliative RT using two different modalities (electron beam and photon beam therapies).
RESULTS: Both patients achieved major and durable responses at 4 irradiated sites, with excellent tolerance and no grade ≥ 3 toxicities. Complete response occurred in 3 of the disease areas (all locoregional) and partial response in 1 metastatic lesion.
CONCLUSION: Palliative radiotherapy after progression to IO was safe and demonstrated profound and durable responses in the cases presented.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:150 |
|---|---|
| Enthalten in: |
Oral oncology - 150(2024) vom: 02. März, Seite 106719 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cabezas-Camarero, Santiago [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Durvalumab |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 11.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.oraloncology.2024.106719 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368253392 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368253392 | ||
| 003 | DE-627 | ||
| 005 | 20240311232251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240210s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2024.106719 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM368253392 | ||
| 035 | |a (NLM)38335850 | ||
| 035 | |a (PII)S1368-8375(24)00037-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cabezas-Camarero, Santiago |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: The immuno-modulatory effects of ionizing radiation are well-known and preclinical studies suggest a synergistic effect of combining radiotherapy (RT) and IO. However, data regarding the clinical activity and safety of this approach are limited | ||
| 520 | |a METHODS: We present the cases of two patients with SCCHN primary progressing to PDL1-based IO within a clinical trial (NCT03383094), that received subsequent but not concurrent palliative RT using two different modalities (electron beam and photon beam therapies) | ||
| 520 | |a RESULTS: Both patients achieved major and durable responses at 4 irradiated sites, with excellent tolerance and no grade ≥ 3 toxicities. Complete response occurred in 3 of the disease areas (all locoregional) and partial response in 1 metastatic lesion | ||
| 520 | |a CONCLUSION: Palliative radiotherapy after progression to IO was safe and demonstrated profound and durable responses in the cases presented | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Durvalumab | |
| 650 | 4 | |a Electron beam radiotherapy | |
| 650 | 4 | |a Head and neck cancer | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a PDL1 | |
| 650 | 4 | |a Photon beam radiotherapy | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Vázquez Masedo, Gonzalo |e verfasserin |4 aut | |
| 700 | 1 | |a Puebla-Díaz, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Corona, Juan Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Segura, Pedro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oral oncology |d 1998 |g 150(2024) vom: 02. März, Seite 106719 |w (DE-627)NLM091475074 |x 1879-0593 |7 nnns |
| 773 | 1 | 8 | |g volume:150 |g year:2024 |g day:02 |g month:03 |g pages:106719 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.oraloncology.2024.106719 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 150 |j 2024 |b 02 |c 03 |h 106719 | ||